Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 295

1.

The pattern of neuronal loss and survival may reflect differential expression of proteasome activators in Parkinson's disease.

McNaught KS, Jnobaptiste R, Jackson T, Jengelley TA.

Synapse. 2010 Mar;64(3):241-50. doi: 10.1002/syn.20719.

PMID:
19924695
[PubMed - indexed for MEDLINE]
2.

Altered proteasomal function in sporadic Parkinson's disease.

McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW.

Exp Neurol. 2003 Jan;179(1):38-46.

PMID:
12504866
[PubMed - indexed for MEDLINE]
3.

Inhibition of proteasome activity sensitizes dopamine neurons to protein alterations and oxidative stress.

Mytilineou C, McNaught KS, Shashidharan P, Yabut J, Baptiste RJ, Parnandi A, Olanow CW.

J Neural Transm. 2004 Oct;111(10-11):1237-51.

PMID:
15480836
[PubMed - indexed for MEDLINE]
4.

Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease.

McNaught KS, Belizaire R, Jenner P, Olanow CW, Isacson O.

Neurosci Lett. 2002 Jul 5;326(3):155-8.

PMID:
12095645
[PubMed - indexed for MEDLINE]
5.

Proteasome inhibitor MG-132 induces dopaminergic degeneration in cell culture and animal models.

Sun F, Anantharam V, Zhang D, Latchoumycandane C, Kanthasamy A, Kanthasamy AG.

Neurotoxicology. 2006 Sep;27(5):807-15. Epub 2006 Jun 29.

PMID:
16870259
[PubMed - indexed for MEDLINE]
6.

A comparison of changes in proteasomal subunit expression in the substantia nigra in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.

Bukhatwa S, Zeng BY, Rose S, Jenner P.

Brain Res. 2010 Apr 22;1326:174-83. doi: 10.1016/j.brainres.2010.02.045. Epub 2010 Feb 20.

PMID:
20176003
[PubMed - indexed for MEDLINE]
7.

Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70.

Mandel S, Grunblatt E, Riederer P, Amariglio N, Jacob-Hirsch J, Rechavi G, Youdim MB.

Ann N Y Acad Sci. 2005 Aug;1053:356-75. Review.

PMID:
16179542
[PubMed - indexed for MEDLINE]
8.

Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures.

McNaught KS, Mytilineou C, Jnobaptiste R, Yabut J, Shashidharan P, Jennert P, Olanow CW.

J Neurochem. 2002 Apr;81(2):301-6.

PMID:
12064477
[PubMed - indexed for MEDLINE]
9.

The role of ubiquitin linkages on alpha-synuclein induced-toxicity in a Drosophila model of Parkinson's disease.

Lee FK, Wong AK, Lee YW, Wan OW, Chan HY, Chung KK.

J Neurochem. 2009 Jul;110(1):208-19. doi: 10.1111/j.1471-4159.2009.06124.x. Epub 2009 Apr 27.

PMID:
19457126
[PubMed - indexed for MEDLINE]
10.

Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease.

Xie W, Li X, Li C, Zhu W, Jankovic J, Le W.

J Neurochem. 2010 Oct;115(1):188-99. doi: 10.1111/j.1471-4159.2010.06914.x. Epub 2010 Aug 19.

PMID:
20649845
[PubMed - indexed for MEDLINE]
11.
12.

A comparative study of proteasomal inhibition and apoptosis induced in N27 mesencephalic cells by dopamine and MG132.

Zafar KS, Inayat-Hussain SH, Ross D.

J Neurochem. 2007 Aug;102(3):913-21. Epub 2007 May 14.

PMID:
17504267
[PubMed - indexed for MEDLINE]
13.

Multiple molecular pathways are involved in the neuroprotection of GDNF against proteasome inhibitor induced dopamine neuron degeneration in vivo.

Du Y, Li X, Yang D, Zhang X, Chen S, Huang K, Le W.

Exp Biol Med (Maywood). 2008 Jul;233(7):881-90. doi: 10.3181/0712-RM-329. Epub 2008 Apr 29.

PMID:
18445767
[PubMed - indexed for MEDLINE]
14.

Aggresome-related biogenesis of Lewy bodies.

McNaught KS, Shashidharan P, Perl DP, Jenner P, Olanow CW.

Eur J Neurosci. 2002 Dec;16(11):2136-48.

PMID:
12473081
[PubMed - indexed for MEDLINE]
15.

MPTP treatment of common marmosets impairs proteasomal enzyme activity and decreases expression of structural and regulatory elements of the 26S proteasome.

Zeng BY, Iravani MM, Lin ST, Irifune M, Kuoppamäki M, Al-Barghouthy G, Smith L, Jackson MJ, Rose S, Medhurst AD, Jenner P.

Eur J Neurosci. 2006 Apr;23(7):1766-74.

PMID:
16623833
[PubMed - indexed for MEDLINE]
16.

Proteasome inhibition causes nigral degeneration with inclusion bodies in rats.

McNaught KS, Björklund LM, Belizaire R, Isacson O, Jenner P, Olanow CW.

Neuroreport. 2002 Aug 7;13(11):1437-41.

PMID:
12167769
[PubMed - indexed for MEDLINE]
17.

The vulnerability of nigral neurons to Parkinson's disease is unrelated to their intrinsic capacity for dopamine synthesis: an in situ hybridization study.

Kingsbury AE, Marsden CD, Foster OJ.

Mov Disord. 1999 Mar;14(2):206-18.

PMID:
10091611
[PubMed - indexed for MEDLINE]
18.

Comparison of the neurotoxic effects of proteasomal inhibitors in primary mesencephalic cultures.

Reaney SH, Johnston LC, Langston WJ, Di Monte DA.

Exp Neurol. 2006 Dec;202(2):434-40. Epub 2006 Aug 22.

PMID:
16920101
[PubMed - indexed for MEDLINE]
19.

Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system.

Betarbet R, Canet-Aviles RM, Sherer TB, Mastroberardino PG, McLendon C, Kim JH, Lund S, Na HM, Taylor G, Bence NF, Kopito R, Seo BB, Yagi T, Yagi A, Klinefelter G, Cookson MR, Greenamyre JT.

Neurobiol Dis. 2006 May;22(2):404-20. Epub 2006 Jan 24.

PMID:
16439141
[PubMed - indexed for MEDLINE]
20.

Proteasome mediates dopaminergic neuronal degeneration, and its inhibition causes alpha-synuclein inclusions.

Sawada H, Kohno R, Kihara T, Izumi Y, Sakka N, Ibi M, Nakanishi M, Nakamizo T, Yamakawa K, Shibasaki H, Yamamoto N, Akaike A, Inden M, Kitamura Y, Taniguchi T, Shimohama S.

J Biol Chem. 2004 Mar 12;279(11):10710-9. Epub 2003 Dec 12.

PMID:
14672949
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk